Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

H. Borghaei, KJ. O'Byrne, L. Paz-Ares, TE. Ciuleanu, X. Yu, A. Pluzanski, A. Nagrial, L. Havel, RD. Kowalyszyn, CA. Valette, JR. Brahmer, M. Reck, SS. Ramalingam, L. Zhang, I. Ntambwe, SK. Rabindran, FE. Nathan, D. Balli, YL. Wu

. 2023 ; 8 (6) : 102065. [pub] 20231120

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007885

BACKGROUND: In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus chemotherapy. We report results from CheckMate 227 Part 2, which evaluated nivolumab plus chemotherapy versus chemotherapy in patients with metastatic NSCLC regardless of tumor PD-L1 expression. PATIENTS AND METHODS: Seven hundred and fifty-five patients with systemic therapy-naive, stage IV/recurrent NSCLC without EGFR mutations or ALK alterations were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus chemotherapy or chemotherapy. Primary endpoint was OS with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC. OS in all randomized patients was a hierarchically tested secondary endpoint. RESULTS: At 19.5 months' minimum follow-up, no significant improvement in OS was seen with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC [median OS 18.8 versus 15.6 months, hazard ratio (HR) 0.86, 95.62% confidence interval (CI) 0.69-1.08, P = 0.1859]. Descriptive analyses showed OS improvement with nivolumab plus chemotherapy versus chemotherapy in all randomized patients (median OS 18.3 versus 14.7 months, HR 0.81, 95.62% CI 0.67-0.97) and in an exploratory analysis in squamous NSCLC (median OS 18.3 versus 12.0 months, HR 0.69, 95% CI 0.50-0.97). A trend toward improved OS was seen with nivolumab plus chemotherapy versus chemotherapy, regardless of the tumor mutation status of STK11 or TP53, regardless of tumor mutational burden, and in patients with intermediate/poor Lung Immune Prognostic Index scores. Safety with nivolumab plus chemotherapy was consistent with previous reports of first-line settings. CONCLUSIONS: CheckMate 227 Part 2 did not meet the primary endpoint of OS with nivolumab plus chemotherapy versus chemotherapy in patients with metastatic nonsquamous NSCLC. Descriptive analyses showed prolonged OS with nivolumab plus chemotherapy in all-randomized and squamous NSCLC populations, suggesting that this combination may benefit patients with untreated metastatic NSCLC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007885
003      
CZ-PrNML
005      
20240507094436.0
007      
ta
008      
240412s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.esmoop.2023.102065 $2 doi
035    __
$a (PubMed)37988950
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Borghaei, H $u Fox Chase Cancer Center, Philadelphia, USA. Electronic address: Hossein.Borghaei@fccc.edu
245    10
$a Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial / $c H. Borghaei, KJ. O'Byrne, L. Paz-Ares, TE. Ciuleanu, X. Yu, A. Pluzanski, A. Nagrial, L. Havel, RD. Kowalyszyn, CA. Valette, JR. Brahmer, M. Reck, SS. Ramalingam, L. Zhang, I. Ntambwe, SK. Rabindran, FE. Nathan, D. Balli, YL. Wu
520    9_
$a BACKGROUND: In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus chemotherapy. We report results from CheckMate 227 Part 2, which evaluated nivolumab plus chemotherapy versus chemotherapy in patients with metastatic NSCLC regardless of tumor PD-L1 expression. PATIENTS AND METHODS: Seven hundred and fifty-five patients with systemic therapy-naive, stage IV/recurrent NSCLC without EGFR mutations or ALK alterations were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus chemotherapy or chemotherapy. Primary endpoint was OS with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC. OS in all randomized patients was a hierarchically tested secondary endpoint. RESULTS: At 19.5 months' minimum follow-up, no significant improvement in OS was seen with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC [median OS 18.8 versus 15.6 months, hazard ratio (HR) 0.86, 95.62% confidence interval (CI) 0.69-1.08, P = 0.1859]. Descriptive analyses showed OS improvement with nivolumab plus chemotherapy versus chemotherapy in all randomized patients (median OS 18.3 versus 14.7 months, HR 0.81, 95.62% CI 0.67-0.97) and in an exploratory analysis in squamous NSCLC (median OS 18.3 versus 12.0 months, HR 0.69, 95% CI 0.50-0.97). A trend toward improved OS was seen with nivolumab plus chemotherapy versus chemotherapy, regardless of the tumor mutation status of STK11 or TP53, regardless of tumor mutational burden, and in patients with intermediate/poor Lung Immune Prognostic Index scores. Safety with nivolumab plus chemotherapy was consistent with previous reports of first-line settings. CONCLUSIONS: CheckMate 227 Part 2 did not meet the primary endpoint of OS with nivolumab plus chemotherapy versus chemotherapy in patients with metastatic nonsquamous NSCLC. Descriptive analyses showed prolonged OS with nivolumab plus chemotherapy in all-randomized and squamous NSCLC populations, suggesting that this combination may benefit patients with untreated metastatic NSCLC.
650    _2
$a lidé $7 D006801
650    12
$a nemalobuněčný karcinom plic $x farmakoterapie $x genetika $x patologie $7 D002289
650    _2
$a nivolumab $x škodlivé účinky $7 D000077594
650    _2
$a antigeny CD274 $x metabolismus $7 D060890
650    12
$a nádory plic $x farmakoterapie $x genetika $x patologie $7 D008175
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    12
$a spinocelulární karcinom $x chemicky indukované $x farmakoterapie $7 D002294
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
700    1_
$a O'Byrne, K J $u Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia
700    1_
$a Paz-Ares, L $u Hospital Universitario 12 de Octubre, Universidad Complutense & CiberOnc, Madrid, Spain
700    1_
$a Ciuleanu, T-E $u Institutul Oncologic Prof. Dr. Ion Chiricuţă and UNF Iuliu Haţieganu University, Cluj-Napoca, Romania
700    1_
$a Yu, X $u Zhejiang Cancer Hospital, Hangzhou, China
700    1_
$a Pluzanski, A $u Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Nagrial, A $u Blacktown Hospital, Sydney, Australia
700    1_
$a Havel, Libor, $u Thomayer Hospital, Charles University, Prague, Czech Republic $d 1967-2023 $7 xx0065540
700    1_
$a Kowalyszyn, R D $u Clínica Viedma, Viedma, Argentina
700    1_
$a Valette, C A $u Hôpital Sainte -Musse, Toulon, France
700    1_
$a Brahmer, J R $u Johns Hopkins, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
700    1_
$a Reck, M $u Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany
700    1_
$a Ramalingam, S S $u Winship Cancer Institute, Emory University, Atlanta, USA
700    1_
$a Zhang, L $u Sun Yat-Sen University Cancer Center, Guangdong, China
700    1_
$a Ntambwe, I $u Bristol Myers Squibb, Princeton, USA
700    1_
$a Rabindran, S K $u Bristol Myers Squibb, Princeton, USA
700    1_
$a Nathan, F E $u Bristol Myers Squibb, Princeton, USA
700    1_
$a Balli, D $u Bristol Myers Squibb, Princeton, USA
700    1_
$a Wu, Y-L $u Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong, China
773    0_
$w MED00196632 $t ESMO open $x 2059-7029 $g Roč. 8, č. 6 (2023), s. 102065
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37988950 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240507094433 $b ABA008
999    __
$a ok $b bmc $g 2081724 $s 1217652
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 8 $c 6 $d 102065 $e 20231120 $i 2059-7029 $m ESMO open $n ESMO Open $x MED00196632
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace